Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations
- PMID: 12376936
- DOI: 10.1002/ajmg.10660
Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations
Abstract
We examined 26 individuals with clinical and electron microscopic signs of late infantile neuronal ceroid lipofuscinosis (LINCL). In 22 cases, we found both pathogenic alleles. Sixteen patients exclusively carried either one or a combination of the two common mutations R208X and IVS5-1G > C. In the remaining cases, four missense mutations could be detected, of which R127Q, N286S, and T353P represent novel, previously not described alleles. A clinical performance score was developed by rating motor, visual, and verbal functions and the incidence of cerebral seizures in 3-month intervals during the course of the disease. A Total Disability Score was derived by summing up the single scores for motor, visual, and verbal functions. The 16 individuals with the two common mutations were grouped together (referred to as standard patients), and the 5th, 50th, and 95th centiles were calculated and graphically depicted over time. The scores for motor function and language ability dropped earliest and progressed very similarly in the standard patients. The performance curves of two children with the N286S mutation slightly diverged from the 95th centile. However, the performance curves of one patient with atypical LINCL carrying the R127Q mutation fell far beyond the 95th centile. The presented performance rating clearly and quantitatively delineates the disease course of the LINCL patients and hence offers a useful tool for clinical evaluation of future therapeutic interventions. In addition, the described performance score system can be applied to other types of neuronal ceroid lipofuscinoses and could be adapted to various other neurodegenerative diseases of childhood.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
-
Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes.Hum Mol Genet. 2004 Oct 15;13(20):2483-91. doi: 10.1093/hmg/ddh264. Epub 2004 Aug 18. Hum Mol Genet. 2004. PMID: 15317752
-
Neurological deterioration in late infantile neuronal ceroid lipofuscinosis.Neurology. 2007 Aug 7;69(6):521-35. doi: 10.1212/01.wnl.0000267885.47092.40. Neurology. 2007. PMID: 17679671
-
R208X mutation in CLN2 gene associated with reduced cerebrospinal fluid pterins in a girl with classic late infantile neuronal ceroid lipofuscinosis.Croat Med J. 2003 Aug;44(4):489-93. Croat Med J. 2003. PMID: 12950156
-
Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5.Hum Mutat. 1999;14(3):199-215. doi: 10.1002/(SICI)1098-1004(1999)14:33.0.CO;2-A. Hum Mutat. 1999. PMID: 10477428 Review.
-
Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3.Mol Genet Metab. 2000 Sep-Oct;71(1-2):207-11. doi: 10.1006/mgme.2000.3056. Mol Genet Metab. 2000. PMID: 11001812 Review.
Cited by
-
Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.Lancet Child Adolesc Health. 2018 Aug;2(8):582-590. doi: 10.1016/S2352-4642(18)30179-2. Epub 2018 Jul 2. Lancet Child Adolesc Health. 2018. PMID: 30119717 Free PMC article.
-
Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy.Ther Clin Risk Manag. 2020 Mar 30;16:213-222. doi: 10.2147/TCRM.S241048. eCollection 2020. Ther Clin Risk Manag. 2020. PMID: 32280231 Free PMC article. Review.
-
Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.Hum Gene Ther Methods. 2012 Oct;23(5):324-35. doi: 10.1089/hgtb.2012.120. Epub 2012 Nov 6. Hum Gene Ther Methods. 2012. PMID: 23131032 Free PMC article.
-
Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials.Front Neurol. 2022 Feb 8;13:785841. doi: 10.3389/fneur.2022.785841. eCollection 2022. Front Neurol. 2022. PMID: 35211079 Free PMC article. Review.
-
Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.Curr Pharm Biotechnol. 2011 Jun;12(6):867-83. doi: 10.2174/138920111795542633. Curr Pharm Biotechnol. 2011. PMID: 21235444 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases